Click here to get full coverage on Outlook Therapeutics (OTLK) price target decreased by 27.91% to 3.95 - MSN

Outlook Therapeutics (OTLK) price target decreased by 27.91% to 3.95  MSN

Outlook Therapeutics (OTLK) price target decreased by 27.91% to 3.95 - MSN

Click here to get full coverage on OTLK SEC Filings - Outlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

OTLK SEC Filings - Outlook Therapeutics Inc 10-K, 10-Q, 8-K Forms  Stock Titan

OTLK SEC Filings - Outlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on OTLK Apr 2026 5.000 put (OTLK260417P00005000) Interactive Stock Chart - Yahoo! Finance Canada

OTLK Apr 2026 5.000 put (OTLK260417P00005000) Interactive Stock Chart  Yahoo! Finance Canada

OTLK Apr 2026 5.000 put (OTLK260417P00005000) Interactive Stock Chart - Yahoo! Finance Canada

Click here to get full coverage on OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - Yahoo Finance

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know  Yahoo Finance

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics takes $18.4M loan at min 9.5% to cut note balance - Stock Titan

Outlook Therapeutics takes $18.4M loan at min 9.5% to cut note balance  Stock Titan

Outlook Therapeutics takes $18.4M loan at min 9.5% to cut note balance - Stock Titan

Click here to get full coverage on OTLK May 2026 2.000 put (OTLK260515P00002000) Interactive Stock Chart - Yahoo! Finance Canada

OTLK May 2026 2.000 put (OTLK260515P00002000) Interactive Stock Chart  Yahoo! Finance Canada

OTLK May 2026 2.000 put (OTLK260515P00002000) Interactive Stock Chart - Yahoo! Finance Canada

Click here to get full coverage on Outlook Therapeutics (OTLK) Price Target Increased by 11.90% to 9.59 - MSN

Outlook Therapeutics (OTLK) Price Target Increased by 11.90% to 9.59  MSN

Outlook Therapeutics (OTLK) Price Target Increased by 11.90% to 9.59 - MSN

Click here to get full coverage on First bevacizumab eye drug? Outlook, FDA discuss path for ONS-5010 - Stock Titan

First bevacizumab eye drug? Outlook, FDA discuss path for ONS-5010  Stock Titan

First bevacizumab eye drug? Outlook, FDA discuss path for ONS-5010 - Stock Titan

Click here to get full coverage on OTLK May 2026 2.500 put (OTLK260515P00002500) Stock Price, News, Quote & History - Yahoo! Finance Canada

OTLK May 2026 2.500 put (OTLK260515P00002500) Stock Price, News, Quote & History  Yahoo! Finance Canada

OTLK May 2026 2.500 put (OTLK260515P00002500) Stock Price, News, Quote & History - Yahoo! Finance Canada

Click here to get full coverage on Eye-disease drug developer seeks cash in stock-and-warrant sale - Stock Titan

Eye-disease drug developer seeks cash in stock-and-warrant sale  Stock Titan

Eye-disease drug developer seeks cash in stock-and-warrant sale - Stock Titan

Click here to get full coverage on Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates  Yahoo Finance

Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics (OTLK) refinances debt with $18.36M note amid going concern risks - Stock Titan

Outlook Therapeutics (OTLK) refinances debt with $18.36M note amid going concern risks  Stock Titan

Outlook Therapeutics (OTLK) refinances debt with $18.36M note amid going concern risks - Stock Titan

Click here to get full coverage on Outlook Therapeutics sells 20M shares, closes $5M financing - Stock Titan

Outlook Therapeutics sells 20M shares, closes $5M financing  Stock Titan

Outlook Therapeutics sells 20M shares, closes $5M financing - Stock Titan

Click here to get full coverage on FDA questions eye drug's evidence; Outlook Therapeutics seeks path forward - Stock Titan

FDA questions eye drug's evidence; Outlook Therapeutics seeks path forward  Stock Titan

FDA questions eye drug's evidence; Outlook Therapeutics seeks path forward - Stock Titan

Click here to get full coverage on 20M new shares at 25 cents: Outlook prices $5M fundraise - Stock Titan

20M new shares at 25 cents: Outlook prices $5M fundraise  Stock Titan

20M new shares at 25 cents: Outlook prices $5M fundraise - Stock Titan

Click here to get full coverage on Eye drug firm Outlook Therapeutics expands in Europe, seeks FDA talks - Stock Titan

Eye drug firm Outlook Therapeutics expands in Europe, seeks FDA talks  Stock Titan

Eye drug firm Outlook Therapeutics expands in Europe, seeks FDA talks - Stock Titan

Click here to get full coverage on OTLK Technical Analysis & Stock Price Forecast - Intellectia AI

OTLK Technical Analysis & Stock Price Forecast  Intellectia AI

OTLK Technical Analysis & Stock Price Forecast - Intellectia AI

Click here to get full coverage on Retail investors among Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders, saw gain in holdings value after stock jumped 14% last week - simplywall.st

Retail investors among Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders, saw gain in holdings value after stock jumped 14% last week  simplywall.st

Retail investors among Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders, saw gain in holdings value after stock jumped 14% last week - simplywall.st

Click here to get full coverage on Why is OTLK stock falling today? - MSN

Why is OTLK stock falling today? - MSN

Click here to get full coverage on Outlook Therapeutics (OTLK) launches 20M-share offering with detachable warrants - Stock Titan

Outlook Therapeutics (OTLK) launches 20M-share offering with detachable warrants  Stock Titan

Outlook Therapeutics (OTLK) launches 20M-share offering with detachable warrants - Stock Titan

Click here to get full coverage on FDA decision due Dec. 31 on eye drug after first Europe sales - Stock Titan

FDA decision due Dec. 31 on eye drug after first Europe sales  Stock Titan

FDA decision due Dec. 31 on eye drug after first Europe sales - Stock Titan

Click here to get full coverage on [8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan

[8-K] Outlook Therapeutics, Inc. Reports Material Event  Stock Titan

[8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan

Click here to get full coverage on Biggest stock movers Tuesday: LI, OTLK, and more - Seeking Alpha

Biggest stock movers Tuesday: LI, OTLK, and more  Seeking Alpha

Biggest stock movers Tuesday: LI, OTLK, and more - Seeking Alpha

Click here to get full coverage on Shareholders at Outlook Therapeutics (NASDAQ: OTLK) approve board slate - Stock Titan

Shareholders at Outlook Therapeutics (NASDAQ: OTLK) approve board slate  Stock Titan

Shareholders at Outlook Therapeutics (NASDAQ: OTLK) approve board slate - Stock Titan

Click here to get full coverage on New Analyst Forecast: $OTLK Given $0.5 Price Target | OTLK Stock News - Quiver Quantitative

New Analyst Forecast: $OTLK Given $0.5 Price Target | OTLK Stock News  Quiver Quantitative

New Analyst Forecast: $OTLK Given $0.5 Price Target | OTLK Stock News - Quiver Quantitative

Click here to get full coverage on Biotech offers stock options to lure two new hires at $2.01 a share - Stock Titan

Biotech offers stock options to lure two new hires at $2.01 a share  Stock Titan

Biotech offers stock options to lure two new hires at $2.01 a share - Stock Titan

Click here to get full coverage on Why Is OTLK Stock Falling Today? - Stocktwits

Why Is OTLK Stock Falling Today?  Stocktwits

Why Is OTLK Stock Falling Today? - Stocktwits

Click here to get full coverage on FDA rejects eye drug already approved in Europe for wet AMD - Stock Titan

FDA rejects eye drug already approved in Europe for wet AMD  Stock Titan

FDA rejects eye drug already approved in Europe for wet AMD - Stock Titan

Click here to get full coverage on OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug - Zacks Investment Research

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug  Zacks Investment Research

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug - Zacks Investment Research

Click here to get full coverage on Outlook Therapeutics Grants Stock Options to New Employees as Part of Inducement Package | OTLK Stock News - Quiver Quantitative

Outlook Therapeutics Grants Stock Options to New Employees as Part of Inducement Package | OTLK Stock News  Quiver Quantitative

Outlook Therapeutics Grants Stock Options to New Employees as Part of Inducement Package | OTLK Stock News - Quiver Quantitative

Click here to get full coverage on New Analyst Forecast: $OTLK Given $10 Price Target | OTLK Stock News - Quiver Quantitative

New Analyst Forecast: $OTLK Given $10 Price Target | OTLK Stock News  Quiver Quantitative

New Analyst Forecast: $OTLK Given $10 Price Target | OTLK Stock News - Quiver Quantitative

Click here to get full coverage on Live Outlook Therapeutics, Inc. (OTLK) Technical Analysis - Traders Union

Live Outlook Therapeutics, Inc. (OTLK) Technical Analysis  Traders Union

Live Outlook Therapeutics, Inc. (OTLK) Technical Analysis - Traders Union

Click here to get full coverage on Biotech dealmaker from $14B Pfizer buyout joins Outlook Therapeutics - Stock Titan

Biotech dealmaker from $14B Pfizer buyout joins Outlook Therapeutics  Stock Titan

Biotech dealmaker from $14B Pfizer buyout joins Outlook Therapeutics - Stock Titan

Click here to get full coverage on Outlook Therapeutics (NASDAQ: OTLK) trims board to nine directors - Stock Titan

Outlook Therapeutics (NASDAQ: OTLK) trims board to nine directors  Stock Titan

Outlook Therapeutics (NASDAQ: OTLK) trims board to nine directors - Stock Titan

Click here to get full coverage on Outlook Therapeutics Reports Fiscal Year 2025 Financial Results and Market Developments for LYTENAVA - Quiver Quantitative

Outlook Therapeutics Reports Fiscal Year 2025 Financial Results and Market Developments for LYTENAVA  Quiver Quantitative

Outlook Therapeutics Reports Fiscal Year 2025 Financial Results and Market Developments for LYTENAVA - Quiver Quantitative

Click here to get full coverage on Outlook Therapeutics (OTLK) Launches Public Offering, Shares Sli - GuruFocus

Outlook Therapeutics (OTLK) Launches Public Offering, Shares Sli  GuruFocus

Outlook Therapeutics (OTLK) Launches Public Offering, Shares Sli - GuruFocus

Click here to get full coverage on Outlook Therapeutics (Nasdaq: OTLK) ONS-5010 BLA Accepted; 60-day FDA review for wet AMD - Stock Titan

Outlook Therapeutics (Nasdaq: OTLK) ONS-5010 BLA Accepted; 60-day FDA review for wet AMD  Stock Titan

Outlook Therapeutics (Nasdaq: OTLK) ONS-5010 BLA Accepted; 60-day FDA review for wet AMD - Stock Titan

Click here to get full coverage on Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates  Yahoo Finance

Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics Receives Complete Response Letter from FDA Regarding ONS-5010/LYTENAVA™ BLA for Wet AMD Treatment - Quiver Quantitative

Outlook Therapeutics Receives Complete Response Letter from FDA Regarding ONS-5010/LYTENAVA™ BLA for Wet AMD Treatment  Quiver Quantitative

Outlook Therapeutics Receives Complete Response Letter from FDA Regarding ONS-5010/LYTENAVA™ BLA for Wet AMD Treatment - Quiver Quantitative

Click here to get full coverage on Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week - Yahoo Finance

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week  Yahoo Finance

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics Announces Board Resignation and Size Reduction - The Globe and Mail

Outlook Therapeutics Announces Board Resignation and Size Reduction  The Globe and Mail

Outlook Therapeutics Announces Board Resignation and Size Reduction - The Globe and Mail

Click here to get full coverage on Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again (NASDAQ:OTLK) - Seeking Alpha

Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again (NASDAQ:OTLK)  Seeking Alpha

Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again (NASDAQ:OTLK) - Seeking Alpha

Click here to get full coverage on FDA Feedback Prompts Outlook Therapeutics to Fast-Track BLA Resubmission for Wet AMD Treatment - Stock Titan

FDA Feedback Prompts Outlook Therapeutics to Fast-Track BLA Resubmission for Wet AMD Treatment  Stock Titan

FDA Feedback Prompts Outlook Therapeutics to Fast-Track BLA Resubmission for Wet AMD Treatment - Stock Titan

Click here to get full coverage on Nasdaq warns Outlook Therapeutics (OTLK) on sub-$1 share price and listing risk - Stock Titan

Nasdaq warns Outlook Therapeutics (OTLK) on sub-$1 share price and listing risk  Stock Titan

Nasdaq warns Outlook Therapeutics (OTLK) on sub-$1 share price and listing risk - Stock Titan

Click here to get full coverage on Why is Outlook Therapeutics (OTLK) Stock Down 61% in Pre-Market Trading? - TipRanks

Why is Outlook Therapeutics (OTLK) Stock Down 61% in Pre-Market Trading?  TipRanks

Why is Outlook Therapeutics (OTLK) Stock Down 61% in Pre-Market Trading? - TipRanks

Click here to get full coverage on Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - GlobeNewswire

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development  GlobeNewswire

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - Quiver Quantitative

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development  Quiver Quantitative

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - Quiver Quantitative

Click here to get full coverage on Outlook Therapeutics gets FDA review for wet AMD drug (OTLK) - Seeking Alpha

Outlook Therapeutics gets FDA review for wet AMD drug (OTLK)  Seeking Alpha

Outlook Therapeutics gets FDA review for wet AMD drug (OTLK) - Seeking Alpha

Click here to get full coverage on Outlook Therapeutics Announces Closing of $5.0 Million Public Offering - ChartMill

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering  ChartMill

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering - ChartMill

Click here to get full coverage on Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date - TechStock²

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date  TechStock²

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date - TechStock²

Click here to get full coverage on Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewswire

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update  GlobeNewswire

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics (OTLK) Q1 2026 loss widens as FDA flags ONS-5010 - Stock Titan

Outlook Therapeutics (OTLK) Q1 2026 loss widens as FDA flags ONS-5010  Stock Titan

Outlook Therapeutics (OTLK) Q1 2026 loss widens as FDA flags ONS-5010 - Stock Titan

Click here to get full coverage on Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering - ChartMill

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering  ChartMill

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering - ChartMill

Click here to get full coverage on FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010 - Stock Titan

FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010  Stock Titan

FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010 - Stock Titan

Click here to get full coverage on Outlook Therapeutics (OTLK) Awaits FDA Decision Amid Revenue Rep - GuruFocus

Outlook Therapeutics (OTLK) Awaits FDA Decision Amid Revenue Rep  GuruFocus

Outlook Therapeutics (OTLK) Awaits FDA Decision Amid Revenue Rep - GuruFocus

Click here to get full coverage on US FDA declines to approve Outlook's eye disease drug for second time in 2025 - Reuters

US FDA declines to approve Outlook's eye disease drug for second time in 2025  Reuters

US FDA declines to approve Outlook's eye disease drug for second time in 2025 - Reuters

Click here to get full coverage on OTLK: Analyst Maintains Neutral Rating and Price Target | OTLK S - GuruFocus

OTLK: Analyst Maintains Neutral Rating and Price Target | OTLK S  GuruFocus

OTLK: Analyst Maintains Neutral Rating and Price Target | OTLK S - GuruFocus

Click here to get full coverage on Outlook Therapeutics Announces FDA Acceptance of ONS-5010 BLA Resubmission with PDUFA Goal Date Set for December 31, 2025 | OTLK Stock News - Quiver Quantitative

Outlook Therapeutics Announces FDA Acceptance of ONS-5010 BLA Resubmission with PDUFA Goal Date Set for December 31, 2025 | OTLK Stock News  Quiver Quantitative

Outlook Therapeutics Announces FDA Acceptance of ONS-5010 BLA Resubmission with PDUFA Goal Date Set for December 31, 2025 | OTLK Stock News - Quiver Quantitative

Click here to get full coverage on Outlook Therapeutics Shareholders Back Board, Pay, and Auditor - The Globe and Mail

Outlook Therapeutics Shareholders Back Board, Pay, and Auditor  The Globe and Mail

Outlook Therapeutics Shareholders Back Board, Pay, and Auditor - The Globe and Mail

Click here to get full coverage on FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock - Stock Titan

FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock  Stock Titan

FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock - Stock Titan

Click here to get full coverage on Outlook Therapeutics commences $5.0M best-efforts offering of common stock with 1-for-1 warrants - tradingview.com

Outlook Therapeutics commences $5.0M best-efforts offering of common stock with 1-for-1 warrants  tradingview.com

Outlook Therapeutics commences $5.0M best-efforts offering of common stock with 1-for-1 warrants - tradingview.com

Click here to get full coverage on Outlook Therapeutics CEO Bob Jahr to Speak at Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative

Outlook Therapeutics CEO Bob Jahr to Speak at Piper Sandler 37th Annual Healthcare Conference  Quiver Quantitative

Outlook Therapeutics CEO Bob Jahr to Speak at Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative

Click here to get full coverage on A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits

A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares  Stocktwits

A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits

Click here to get full coverage on Outlook Therapeutics (OTLK) Expects FDA Decision on ONS-5010 by Year-End - GuruFocus

Outlook Therapeutics (OTLK) Expects FDA Decision on ONS-5010 by Year-End  GuruFocus

Outlook Therapeutics (OTLK) Expects FDA Decision on ONS-5010 by Year-End - GuruFocus

Click here to get full coverage on Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter - GlobeNewswire

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter  GlobeNewswire

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics Announces Board Resignation and Size Reduction - TipRanks

Outlook Therapeutics Announces Board Resignation and Size Reduction  TipRanks

Outlook Therapeutics Announces Board Resignation and Size Reduction - TipRanks

Click here to get full coverage on OTLK Stock Flying High: What Fuels the Surge? - StocksToTrade

OTLK Stock Flying High: What Fuels the Surge?  StocksToTrade

OTLK Stock Flying High: What Fuels the Surge? - StocksToTrade

Click here to get full coverage on Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - tradingview.com

Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard  tradingview.com

OTLK

Price Chart

Key Statistics

Technicals

About OTLK

Latest News

Outlook Therapeutics (OTLK) price target decreased by 27.91% to 3.95 - MSN

OTLK SEC Filings - Outlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

OTLK Apr 2026 5.000 put (OTLK260417P00005000) Interactive Stock Chart - Yahoo! Finance Canada

Advanced Charts

Top Gainers

Top Losers